Picoplatin for SCLC: Review of Data Presented at ASCO

Article

Here is the discussion about the study of picoplatin vs. placebo for relapsed SCLC, from the post-ASCO review that I did with Dr. Pennell. Unfortunately, this work was an overall disappointment, not quite beating placebo in a setting for which we already have a more active alternative. Here's the transcript and figures from that portion of the discussion.

=======================================

Case Discussion with Dr. Nasser Hanna: Managing Extensive Stage Small Cell Lung Cancer

Article

Here is the last case I discussed several months ago with Dr. Nasser Hanna, lung cancer expert at Indiana University. After two cases that included never or light former smokers, which he joked that I saw far more of than he did, we changed direction to cover current issues in managing extensive stage small cell lung cancer, a field in which he's been a leader.

==============================================================

Can BCL-2 inhibitors make progress in SCLC?

Article

The development of targeted therapy drugs has improved survival for patients with NSCLC, and the “pipeline” of agents in development awaiting further testing in clinical trials seems to be increasing by the day. The improvements in survival in particular subpopulations of patients with NSCLC inspires both patients and physicians who treat lung cancer to hope that similar gains may be made, perhaps incrementally, for patients in all subpopulations of NSCLC.

Interview with Dr. Toni Wozniak, Covering SCLC Basics

Article

I recently had the opportunity to sit down with Dr. Toni Wozniak, Moedical Oncologist and lung cancer expert at the Barbara A. Karmanos Cancer Center at Wayne State University in Detroit, MI. We covered several topics, including SCLC, the subject of this podcast. It is an audio interview but includes a few figures that are synchronized with the audio on the video version, or you can download the pdf of the figures and just follow along with the audio.

[powerpress]